SMMT · Summit Therapeutics Inc. · Documents
$15.10
-0.23 (-1.50%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 23, 2026
Market Cap
$11.85B
Shares
797.75M
Volume · Oct 28
95.2K
Avg daily vol (3M)
6.06M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| DEF 14A | Summit Therapeutics is holding a virtual special meeting on November 4, 2026 at 11:00 a.m. Eastern Time to seek stockholder approval of an amendment increasing authorized common stock from 1,000,000,000 to 2,000,000,000 shares. | 2026-10-19 | 2026-11-04 | |
| PRE 14A | Summit Therapeutics Inc. seeks approval to increase authorized common stock by 1,000,000,000, from 1,000,000,000 to 2,000,000,000, enabling conversion of 108,955,369 common shares from preferred stock and meeting a December 31, 2026 obligation. | 2026-10-06 | — | |
| 8-K | Summit Therapeutics Inc. entered a September 28, 2026 securities purchase agreement with AstraZeneca Holdings B.V. to sell 108,955.3686 Class A Convertible Preferred Shares at $18,356.14 each for $2.0 billion in aggregate gross proceeds. | 2026-09-29 | 2026-09-28 | |
| 8-K | — | 2026-09-15 | — | |
| 8-K | — | 2026-09-14 | 2026-09-13 | |
| 8-K | — | 2026-09-03 | 2026-09-02 | |
| 8-K | — | 2026-08-26 | 2026-08-25 | |
| 8-K | — | 2026-08-05 | — | |
| 8-K | — | 2026-07-23 | — | |
| 8-K | — | 2026-07-23 | — | |
| 10-Q | — | 2026-07-23 | 2026-06-30 | |
| 8-K | — | 2026-07-22 | — | |
| 8-K | — | 2026-06-12 | 2026-06-10 | |
| 8-K | — | 2026-06-11 | 2026-06-10 | |
| S-3ASR | — | 2026-06-09 | — | |
| Investor Event Transcript | — | 2026-06-08 | 2026-06-30 | |
| 8-K | — | 2026-06-03 | 2026-06-02 | |
| 8-K | — | 2026-06-01 | 2026-05-30 | |
| 10-Q | — | 2026-04-30 | 2026-03-31 | |
| 8-K | — | 2026-04-30 | — | |
| DEFA14A | — | 2026-04-17 | — | |
| DEF 14A | — | 2026-04-17 | — | |
| ARS | — | 2026-04-17 | 2025-12-31 | |
| PRE 14A | — | 2026-04-06 | — | |
| 8-K | — | 2026-02-23 | — | |
| 10-K | — | 2026-02-23 | 2025-12-31 | |
| 8-K | — | 2026-01-29 | — | |
| 8-K | — | 2026-01-12 | — | |
| 8-K | — | 2025-11-07 | — | |
| S-3ASR | — | 2025-10-29 | — | |
| 8-K | — | 2025-10-22 | 2025-10-21 | |
| 10-Q | — | 2025-10-20 | 2025-09-30 | |
| 8-K | — | 2025-10-20 | 2025-10-17 | |
| 8-K | — | 2025-09-08 | 2025-09-07 | |
| 8-K | — | 2025-08-11 | — | |
| 10-Q | — | 2025-08-11 | 2025-06-30 | |
| 8-K | — | 2025-08-11 | — | |
| 8-K | — | 2025-06-20 | 2025-06-16 | |
| 8-K | — | 2025-06-17 | 2025-06-12 | |
| 8-K | — | 2025-05-30 | — | |
| 10-Q | — | 2025-05-01 | 2025-03-31 | |
| 8-K | — | 2025-05-01 | — | |
| DEF 14A | — | 2025-04-29 | 2025-06-12 | |
| ARS | — | 2025-04-29 | 2024-12-31 | |
| 8-K | — | 2025-04-25 | — | |
| 8-K | — | 2025-04-23 | — | |
| 8-K | — | 2025-02-24 | — | |
| 10-K | — | 2025-02-24 | 2024-12-31 | |
| 8-K | — | 2025-01-24 | 2025-01-22 | |
| 8-K | — | 2025-01-13 | — |
Showing 1–50 of 204 filings
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
48 filings
48 filers
Visit website
Investor relations